AN ACT to amend Tennessee Code Annotated, Title 63 and Title 68, relative to stem cell therapies.
SB2586 creates a new Tennessee statutory framework allowing physicians to perform certain stem cell therapies that have not been approved by the U.S. Food and Drug Administration, but only when the treatment is within the physician’s scope of practice and limited to orthopedics, wound care, or pain management. The bill defines key terms such as “stem cell therapy,” “minimally manipulated,” and “human cells, tissues, or cellular or tissue-based products,” and excludes a number of products and materials from coverage, including organs, blood products, animal-derived tissues, and certain minimally manipulated bone marrow.
The bill imposes detailed conditions on the sourcing and handling of stem cells. Facilities must be FDA-registered and also certified or accredited by specified organizations, and the stem cell products must include post-thaw viability analysis showing live cells before use. Physicians must also ensure their contracts with facilities disclose accreditation details and require notice of any change in status. The bill requires advertising disclosures warning patients that the therapy is not FDA-approved and mandates a signed informed-consent form describing the treatment, expected results, risks, benefits, and alternatives. It also exempts certain investigational FDA-approved uses and therapies performed under contracts with accredited institutions.
The bill would amend Tennessee Code Annotated Titles 63 and 68 by adding new regulatory requirements for physicians and stem cell suppliers, and it authorizes the medical and osteopathic boards to adopt rules to implement the law. Violations may lead to professional discipline, and intentional conduct involving fetal or embryonic tissue after abortion is made a Class E felony. The act takes effect immediately for rulemaking purposes and on July 1, 2026, for all other purposes.
The overall sentiment reflected in the available voting history is strongly supportive: the Senate Health and Welfare Committee recommended passage with amendments by a 9-0 vote. No committee transcript is available, so the record does not show detailed debate, but the unanimous vote suggests broad agreement on establishing guardrails for stem cell therapies rather than outright opposition to the practice itself.
The main points of contention likely center on patient safety, medical oversight, and the legality/ethics of non-FDA-approved treatments. The bill appears designed to permit limited use of emerging therapies while restricting unregulated or questionable stem cell practices through accreditation, disclosure, and consent requirements. The felony provision related to fetal or embryonic tissue after abortion is likely the most sensitive provision, alongside the question of whether the bill appropriately balances access to treatment with consumer protection and regulatory control.
The bill would add a new section to Tennessee law governing physician use of stem cell therapies and would create new compliance obligations for physicians, facilities, and professional boards. It affects medical practice regulation under Title 63 and incorporates federal manufacturing and product standards under Title 68-related health provisions, while also exposing violators to professional discipline and, in one circumstance, felony liability. The measure would therefore expand state oversight of stem cell treatments and set conditions under which non-FDA-approved therapies may be offered in Tennessee.
Available voting history indicates favorable sentiment toward the bill, with the Senate Health and Welfare Committee voting 9-0 to recommend passage with amendments. The lack of transcript material limits insight into individual arguments, but the unanimous committee vote suggests the bill was viewed as a regulated, safety-focused approach to stem cell therapy rather than a controversial expansion of medical practice.
The likely areas of contention are the bill’s authorization of non-FDA-approved stem cell therapies, the strict accreditation and manufacturing requirements imposed on providers, and the criminal penalty tied to fetal or embryonic tissue after abortion. Supporters would likely emphasize patient safeguards, informed consent, and limiting the bill to specific therapeutic areas such as orthopedics, wound care, and pain management. Opponents or skeptics would likely focus on whether the bill opens the door to unproven treatments, whether the state should regulate in an area heavily governed by federal standards, and whether the felony provision is overly broad or politically charged.